The results of the randomized study include treatment data from 258 patients with malignant ascites caused by various cancers. Most patients had latestage disease with a median life expectancy of two to three months. The primary endpoint of the study had already demonstrated that patients receiving removab had a fourfold increased puncture-free survival over a therapy with puncture alone (median 46 vs. 11 days, p
Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab® for patients with malignant ascites
The results of the randomized study include treatment data from 258 patients with malignant ascites caused by various cancers. Most patients had latestage disease with a median life expectancy of two to three months. The primary endpoint of the study had already demonstrated that patients receiving removab had a fourfold increased puncture-free survival over a therapy with puncture alone (median 46 vs. 11 days, p